MARKET

SMMT

SMMT

SUMMIT THERAP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.450
+0.020
+0.00%
Closed 16:00 02/20 EST
OPEN
1.460
PREV CLOSE
1.450
HIGH
1.489
LOW
1.400
VOLUME
44.80K
TURNOVER
--
52 WEEK HIGH
2.460
52 WEEK LOW
1.132
MARKET CAP
98.83M
P/E (TTM)
-1.4995
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SMMT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SMMT News

  • AIM Delisting Reminder
  • GlobeNewswire.02/11 10:00
  • Director/PDMR Shareholding
  • GlobeNewswire.02/10 14:15
  • Summit Therapeutics earn $1M milestone on advancement of ridinilazole
  • seekingalpha.02/06 20:56
  • Summit Therapeutics To Receive $1M Milestone Payment From Eurofarma Based On Achievement Of Patient Enrollment Target In Phase 3 Trials Of Ridinilazole
  • Benzinga.02/06 12:13

More

Industry

Biotechnology & Medical Research
+0.09%
Pharmaceuticals & Medical Research
-0.40%

Hot Stocks

Name
Price
%Change

About SMMT

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the infectious disease Clostridium difficile infection (CDI). Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid.
More

Webull offers Summit Therapeutics PLC (SMMT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.